UOC
MRNA icon

UBS O'Connor’s Moderna MRNA Stock Holding History

UBS O'Connor’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-35,000
Closed -$23.4K – 390
2025
Q2 		$23.4K Buy
+35,000
New +$922K ﹤0.01% 337
2024
Q4 		– Sell
-15,000
Closed -$30.9K – 520
2024
Q3 		$30.9K Sell
15,000
-1,000
-6% -$91.8K ﹤0.01% 433
2024
Q2 		$17.9K Sell
16,000
-4,000
-20% -$506K ﹤0.01% 483
2024
Q1 		$68.5K Buy
20,000
+8,000
+67% +$806K ﹤0.01% 431
2023
Q4 		$85.5K Buy
+12,000
New +$1.01M ﹤0.01% 415
2023
Q2 		– Sell
-10,500
Closed -$55.9K – 618
2023
Q1 		$55.9K Buy
+10,500
New +$1.73M ﹤0.01% 545

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS O'Connor's MRNA Position: Q4 2021 in Review

UBS O'Connor sold out of Moderna (MRNA) in Q4 2021, closing a stake of 7,500 shares — an estimated $2.89M sold.

UBS O'Connor first reported a position in MRNA in Q2 2021 and held it in 2 quarters. The position peaked at $2.89M in Q3 2021. 1,109 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

  • UBS O'Connor reported no remaining Moderna position as of Q4 2021 after selling out during the quarter.
  • UBS O'Connor sold 7,500 Moderna shares in Q4 2021, an estimated $2.89M.
  • UBS O'Connor first reported a position in Moderna in Q2 2021 and held it in 2 quarters.
  • UBS O'Connor's Moderna position peaked at $2.89M in Q3 2021.
  • 1,109 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on UBS O'Connor's 13F filing for Q4 2021, filed 14 Feb 2022.